SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (DGX) company, today announced a research collaboration with Mass General Brigham investigators at ...

BALTIMORE, Md. and MONTREAL, July 29, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, ...

SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer ...

Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA). Haystack Oncology developed Haystack MRD, a ...

SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...

BALTIMORE, Jan. 22, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research ...

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of ...

SECAUCUS, N.J., June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously ...

Secaucus-headquartered medical testing provider Quest Diagnostics plans to acquire Haystack Oncology, an early-stage company that developed a technology that helps identify cancer recurrence after ...

Quest Diagnostics’ DGX subsidiary, Haystack Oncology, and Lisata Therapeutics, Inc. LSTA recently announced a research collaboration for using the Haystack MRD (minimal residual disease) technology.